2016
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.
Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology 2016, 30: 1099-103, 1106-8. PMID: 27987203, PMCID: PMC7440297.Peer-Reviewed Original ResearchConceptsRecurrent Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAutologous stem cell transplantationMedical literatureAppropriateness of imagingInnovative targeted therapiesCombined-modality therapyLow-dose therapyACR Appropriateness CriteriaEarly-stage diseaseStem cell transplantationMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literaturePeer-reviewed journalsRecurrent diseaseSalvage optionCell transplantationTargeted therapyClinical conditionsACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. American Journal Of Clinical Oncology 2016, 39: 535-544. PMID: 27643717, PMCID: PMC7433865, DOI: 10.1097/coc.0000000000000331.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHodgkin DiseaseHumansMaleNeoplasm InvasivenessNeoplasm StagingOutcome Assessment, Health CarePractice Guidelines as TopicRadiotherapy DosageRandomized Controlled Trials as TopicRisk AssessmentSocieties, MedicalSurvival AnalysisUnited StatesConceptsStage IModality therapyHodgkin's lymphomaAppropriateness CriteriaMedical literatureAppropriateness of imagingACR Appropriateness CriteriaRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literatureLess chemotherapyPeer-reviewed journalsLate effectsClinical conditionsRadiation therapyAmerican CollegeExpert opinionClinical scenariosExcellent efficacyGuideline developmentAvailable evidence
2013
ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
Hoppe BS, Hodgson DC, Advani R, Dabaja BS, Flowers CR, Ha CS, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology 2013, 27: 786-94. PMID: 24133827.Peer-Reviewed Original ResearchConceptsIndolent lymphomaAppropriateness of imagingOutcomes of patientsMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsPeer-reviewed journalsPrognostic factorsTreatment optionsAppropriateness CriteriaTreatment decisionsClinical conditionsAmerican CollegeGuideline developmentMedical literatureRadiation guidelinesConsensus methodologyLymphomaExpert panelRadiation dosePatientsRadiation techniques